Active, not recruitingPhase 1NCT05309668
Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN
Studying Neurofibromatosis type 1
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AstraZeneca
- Principal Investigator
- Study physician Study physician, MDAstraZeneca
- Intervention
- Selumetinib granule formulation(drug)
- Enrollment
- 36 enrolled
- Eligibility
- 1-6 years · All sexes
- Timeline
- 2022 – 2027
Study locations (15)
- Research Site, Akron, Ohio, United States
- Research Site, Philadelphia, Pennsylvania, United States
- Research Site, Houston, Texas, United States
- Research Site, Richmond, Virginia, United States
- Research Site, Hamburg, Germany
- Research Site, München, Germany
- Research Site, Tübingen, Germany
- Research Site, Milan, Italy
- Research Site, Rome, Italy
- Research Site, Nagoya, Japan
- Research Site, Setagaya City, Japan
- Research Site, Rotterdam, Netherlands
- Research Site, Moscow, Russia
- Research Site, Barcelona, Spain
- Research Site, Madrid, Spain
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05309668 on ClinicalTrials.govOther trials for Neurofibromatosis type 1
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06507748A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)National Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07102394Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1Johns Hopkins University
- RECRUITINGNANCT07221331Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)AstraZeneca
- RECRUITINGNANCT07088991Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsiaAstraZeneca
- RECRUITINGPHASE1NCT06961565PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform NeurofibromasPasithea Therapeutics Corp.
- RECRUITINGNANCT06880991Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative StudyNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06541847A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1Healx Limited
- RECRUITINGNANCT06222203Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)National Cancer Institute (NCI)